x

Search for a research project

* (*) mandatory field

66 Result(s)

Sort by

Terminated research projects = Funded by an IRDiRC member = Member of a ERN =

Research projects

AUSTRIA

NIEDERÖSTERREICH
KREMS AN DER DONAU

STAT3 isoforms in acute myeloid leukemia
Karl Landsteiner Privatuniversität für Gesundheitswissenschaften
Fachbereich Pharmakologie

AUSTRIA

STEIERMARK
GRAZ

Subclonal TP53 mutations in acute myeloid leukemia
Medizinische Universität Graz
Klinische Abteilung für Hämatologie

AUSTRIA

WIEN
ADDRESS: NOT PROVIDED - AT

AUSTRIA

WIEN
ADDRESS: NOT PROVIDED - AT

AUSTRIA

WIEN
WIEN

Find tumor immune evasion strategies by cellular barcoding
St. Anna Kinderkrebsforschung
Children's Cancer Research Institute

AUSTRIA

WIEN
WIEN

Linking CDK6 to the epigenome in AML (acute myeloid leukemia)
Veterinärmedizinische Universität Wien
Institut für Pharmakologie und Toxikologie

BELGIUM

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

MicroAML: Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia
Metabolism & Nutrition (MNut), Louvain Drug Institute
Metabolism & Nutrition

CANADA

Ontario
TORONTO

Funded by an IRDiRC memberCD123-Targeted Auger Electron Radioimmunotherapy of Acute Myelogenous Leukemia (AML)
University of Toronto
Leslie Dan Faculty of Pharmacy, University of Toronto

GERMANY

Baden-Württemberg
FREIBURG

The role of the histone demethylase LSD1 in the pathogenesis of AM (FOR 2674: Aging-related epigenetic remodeling in acute myeloid leukemia)
Zentrum für Klinische Forschung am Universitätsklinikum Freiburg
Sektion Molekulare Hämatologie

GERMANY

Baden-Württemberg
HEIDELBERG

INFORM-Registry: INdividualized Therapy FOr Relapsed Malignancies in Childhood
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie

GERMANY

Niedersachsen
HANNOVER

AML-BFM Register 2017: Clinical registry for children and adolescents with acute myeloid leukemia
KPOH Geschäftsführung Hannover
Kompetenznetz Pädiatrische Onkologie und Hämatologie

GERMANY

Nordrhein-Westfalen
ESSEN

ITALY

EMILIA ROMAGNA
MELDOLA

Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

SPAIN

Andalucía
GRANADA

Funded by an IRDiRC memberA multiOMICS approach to characterize de novo and secondary acute myeloid leukaemia: a study in the context of the NuCLEAR consortium and the GESMD cooperative group
Fundación para la Investigación Biosanitaria de Andalucía Oriental
FIBAO: Fundación para la Investigación Biosanitaria de Andalucía Oriental Alejando Otero

SPAIN

Cataluña
BARCELONA

Funded by an IRDiRC memberNew approaches to WT1 analysis in myeloid malignancies. Utility of single-cell studies
IIB Sant Pau - Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

SPAIN

Cataluña
BARCELONA

Funded by an IRDiRC memberSubclonal AML populations and leukemia stem cell compartment identified using single cell RNA-sequencing and multiparameter flow cytometry: Relevance for response to therapy
IIB Sant Pau - Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

SPAIN

Comunidad Valenciana
VALENCIA

Developing a Molecular Diagnostic Platform for Personalized Medicine for Acute Myeloid Leukemia
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia

SPAIN

Navarra
PAMPLONA

Funded by an IRDiRC memberDifferentiation therapy strategy using novel epigenetic inhibitors for acute myeloid leukemia
IdiSNA - Instituto de Investigación Sanitaria de Navarra
Instituto de Investigación Sanitaria de Navarra

SPAIN

Navarra
PAMPLONA

SWEDEN

Region Stockholm
HUDDINGE

Molecular pathogenesis in myelodysplastic syndromes and acute myeloid leukemia
Karolinska Institutet
Department of Medicine, Huddinge (MedH)

SWEDEN

Region Stockholm
HUDDINGE

SWITZERLAND

Suisse Alémanique
BASEL

SWITZERLAND

Suisse Alémanique
BERN

Targeting Immune Checkpoints to Eliminate Leukemia Stem Cells
Inselspital Universitätsspital
Universitätsklinik für Medizinische Onkologie

SWITZERLAND

Suisse Alémanique
ZÜRICH

The divergent roles of mono- and biallelic TP53 mutations in leukemogenesis
Universitätsspital Zürich
Klinik für Medizinische Onkologie und Hämatologie

UNITED STATES

Maryland
BETHESDA

Funded by an IRDiRC memberHDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
National Center for Advancing Translational Sciences (NCATS-NIH)
Therapeutic Development Branch

UNITED STATES

Maryland
BETHESDA

Funded by an IRDiRC memberThe development of multikinase inhibitors for the treatment of selected cancers
National Center for Advancing Translational Sciences (NCATS-NIH)
National Center for Advancing Translational Sciences

UNITED STATES

Washington
ADDRESS: NOT PROVIDED - US

Funded by an IRDiRC memberTherapeutics for rare and neglected diseases - science
Institution: Information not provided - US

UNITED STATES

Washington
ADDRESS: NOT PROVIDED - US

Funded by an IRDiRC memberMechanistic and translational studies of cbf leukemia
Institution: Information not provided - US

UNITED STATES

Washington
ADDRESS: NOT PROVIDED - US

Funded by an IRDiRC memberMolecular pathogenesis of chromosome 16 inversion in human leukemia
Institution: Information not provided - US

GERMANY

Baden-Württemberg
FREIBURG

Funded by an IRDiRC memberMyPred: Optimizing the Care of Young Individuals with Predisposition to Myeloid Neoplasia
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Pädiatrische Hämatologie und Onkologie

GERMANY

Baden-Württemberg
TÜBINGEN

Funded by an IRDiRC memberMyPred: Optimizing the Care of Young Individuals with Predisposition to Myeloid Neoplasia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie

GERMANY

Hessen
FRANKFURT AM MAIN

Funded by an IRDiRC memberMyPred: Optimizing the Care of Young Individuals with Predisposition to Myeloid Neoplasia
Universitätsklinikum Frankfurt
Schwerpunkt Onkologie, Hämatologie und Hämostaseologie

GERMANY

Nordrhein-Westfalen
DÜSSELDORF

Funded by an IRDiRC memberMyPred: Optimizing the Care of Young Individuals with Predisposition to Myeloid Neoplasia
Universitätsklinikum Düsseldorf
Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie

SWITZERLAND

Suisse Alémanique
BERN

Exploiting metabolic liabilities in leukemic stem cells for targeted therapy of myeloid malignancies
Universitätsspital Inselspital
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor (UKH-HZL)

AUSTRIA

WIEN
WIEN

Christian Doppler Laboratory for Next Generation CAR-T Cells
St. Anna Kinderkrebsforschung
Children's Cancer Research Institute

BELGIUM

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

CANADA

Ontario
TORONTO

GERMANY

Baden-Württemberg
HEIDELBERG

Funded by an IRDiRC memberERA-NET TRANSCAN: BRCAddict - BRCAness as a therapeutic target for solid high-risk childhood tumors
Deutsches Krebsforschungszentrum
KITZ - Hopp-Kindertumorzentrum Heidelberg

ITALY

VENETO
PADOVA

Funded by an IRDiRC memberModulating BMP axis to prevent muscle loss, dismantling of NMJ and denervation in cancer cachexia
Venetian Institute of Molecular Medicine
Fondazione per la ricerca Biomedica avanzata ONLUS

UNITED STATES

Washington
ADDRESS: NOT PROVIDED - US

SPAIN

Madrid
MADRID

Funded by an IRDiRC memberMechanistic models using Machine Learning for therapeutic targets discovery and drug repurposing in Rare Diseases
ISCIII - Instituto de Salud Carlos III
Centro de Investigación Biomédica en Red de Enfermedades Raras

Multicentric Research projects